OPRX earnings

– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "

WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2026. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Tuesday, May 12, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-

-   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today

-   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Thursday, March 5, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific T

-   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan subsequent to the end of Q3 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life scie

WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, November 6, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacifi

Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)T

Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025

WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, May 12, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free

Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.  For the Year EndedDecember 31,Key Performance Indicators (KPIs)* 2024   2023  (in thousands, except percentages)Average revenue per top 20 pharma

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, March 12, 2025, at 8:30 a.m. Eastern Time to discuss full year fiscal 2024 financial results and the fourth quarter period ended December 31, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Wednesday, March 12, 2025Time:8:30 a.m. Easte

- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the third quarter of 2024 increased 30% to $21.3 million, as compared to $

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:   Date:Wednesday, November 13, 2024Time:4:30 p.m. Eastern Time (1:30

–   Q2 revenue of $18.8 million, increasing 36% year-over-year–   Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62%–   Won 8 DAAP deals during Q2 WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended June 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the second quarter of 2024 increased 36% to $18.8 million, as compared to $13.8 million in the same year ago period

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 8, 2024Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)

Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2024 increased 51% to $19.7 million, as compared to $13.0 million in the same year ago period.Gross profit

1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is providing a business update for 2024 and is preannouncing preliminary, unaudited results for select financials for the first quarter of 2024. For the first quarter, the Company expects r

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, March 28, 2024Time:8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Toll Free:1-877-423-9813International:1-201-689-8573Conference ID:13745113Call

- Increases guidance for 2023 and introduces guidance for 2024- Total revenue of $16.3 million- GAAP net loss per share of $(0.17)- Non-GAAP net income per share of $0.09- Total DAAP (fka RWD) deals for the year now stands at 16- Completed acquisition of Medicx Health after quarter end WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2023. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the thir

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has successfully completed its acquisition of Healthy Offers, Inc., dba Medicx Health ("Medicx"), a leading healthcare consumer-focused omnichannel marketing and analytics company. The two companies will operate independently through 2023 with full integration during the first quarter of 2024. The Company will hold a conference call on Monday, November 6, 2023, at 8:30 a.m. Eastern Time to discuss its results for the third qua

Preannounces Preliminary Third Quarter 2023 Results OptimizeRx adds new, proven, profitable technologies to become the most comprehensive healthcare marketing platform in the nation. Consolidated revenue run rate will increase to nearly $100 million and the acquisition is expected to be immediately accretive to earnings. Third quarter 2023 headline numbers to come in ahead of consensus with revenue for OptimizeRx standalone expected to be between $15.2-$15.5 million and non-GAAP net income expected to be $0.6-$1 million. Conference call to start at 8:30am EST on Thursday, October 12, 2023. WALTHAM, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OP

– RWD.AI-enabled portion of the core business sees 186% YOY growth during the first half of 2023 – Non-core business is lagging – Total revenue of $13.8 million – GAAP net loss per share of $(0.24) – Non-GAAP net loss per share of $(0.01) ROCHESTER, Mich., Aug. 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended June 30, 2023. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the second quarter of 2023 decreased 1% to $13.8 million, as co

ROCHESTER, Mich., July 31, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Monday, August 14, 2023 at 4:30 p.m. Eastern Time to discuss its results for the second quarter and half year period ended June 30, 2023. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, August 14, 2023Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Toll Free:1-888-886-7786Internatio

A leading suite of pharma tech solutions combined with deep brand penetration is driving revenue growth, resulting in improved profitability and KPIs through the remainder of 2023 and beyondWith a comprehensive, digitally enabled enterprise point-of-care solution, the OptimizeRx platform now reaches 600 thousand health care professionals (HCPs) through point-of-care channels, 90% of all health system intranet/web portals, and over 2 million HCPs via social media2023 guidance of at least a 10% increase in revenue is reaffirmed as midyear backlog visibility improves year-over-year to 60-70% of full year revenuesExpected achievement of revenue between $100 - $120 million within the next 18 to 2

ROCHESTER, Mich., April 26, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2023. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Wednesday, May 10, 2023Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Toll Free:1-888-886-7786International:1-416-764-8658 Conf

ROCHESTER, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and fiscal year, ended December 31, 2022. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Wednesday, March 8, 2023Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast:https://viavid.webcasts.co

ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, November 8, 2022, at 4:30 p.m. Eastern time to discuss its results for the third quarter, ended September 30, 2022. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Tuesday, November 8, 2022Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast:https://viavid.webcasts.com/starthere.j

ROCHESTER, Mich., July 21, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, August 9, 2022, at 4:30 p.m. Eastern time to discuss its results for the second quarter, ended June 30, 2022. The financial results will be issued in a press release prior to the call. OptimizeRx's management looks forward to the call, which will include a question-and-answer session. Conference Call Information: Date:Tuesday, August 9, 2022Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1559358

ROCHESTER, Mich., April 21, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Wednesday, May 4, 2022, at 4:30 p.m. Eastern time to discuss its results for the first quarter, ended March 31, 2022. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Conference Call Information: Date:Wednesday, May 4, 2022Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=mJzKX2F

ROCHESTER, Mich., Feb. 10, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Thursday, February 24, 2022, at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2021. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question and answer period. Conference Call Information: Date:Thursday, February 24, 2022Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast:https://themediaframe.com/mediaframe/webcast.

ROCHESTER, Mich., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Tuesday, November 9, 2021, at  4:30 p.m. Eastern Time to discuss its results for the third quarter, ended September 30, 2021. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question and answer period. Conference Call Information: Date:Tuesday, November 9, 2021Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast:https://78449.themediaframe.com/dataconf/productusers/vvdb/me

ROCHESTER, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Wednesday, August 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the second quarter, ended June 30, 2021. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question and answer period. Conference Call Information: Date:Wednesday, August 4, 2021Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)Webcast:http://public.viavid.com/index.php?id=146009Toll Free Nu